Entera Bio announced positive post-hoc Phase 2 data for its oral peptide EB613, showing greater bone mineral density gains in postmenopausal women with osteoporosis. This data supports the drug's potential benefit in a high-risk fracture population, aligning with the planned Phase 3 study and potentially de-risking future development.
Entera Bio presented post-hoc Phase 2 data for EB613, an oral peptide for osteoporosis, at the ASBMR 2026 Annual Meeting. The key finding was that EB613 demonstrated greater bone mineral density gains and an anabolic effect in women with osteoporosis (T-scores of ≤-2.5) compared to those with osteopenia. This is significant because it specifically highlights the drug's efficacy in the target population for its upcoming Phase 3 study, which focuses on postmenopausal women with osteoporosis at high risk for fracture. This positive data could de-risk the Phase 3 trial and provides a short-term positive catalyst for ENTX, potentially attracting investor interest and strengthening its long-term development prospects for EB613.